M
Moleculin Biotech, Inc.
MBRXCIK 0001659617NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$0
Net Income
$-33.56M
Total Assets
—
Equity
—
Shares Out
5.34M
Op. Cash Flow
$-22.73M
Business
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on developing oncology and antiviral therapeutics, principally conducting a pivotal Phase 2B/3 (MIRACLE) trial of Annamycin in relapsed/refractory acute myeloid leukemia. Its main product candidates and technology portfolios include Annamycin (liposomal, non‑cardiotoxic anthracycline), the WP1066 immune/transcription modulators, the WP1122 metabolism/glycosylation inhibitors, and related analogs. The company’s operations center on clinical development, preclinical research, licensing and sponsored research collaborations, and investigator‑initiated studies. It conducts global clinical trials in the US, Europe, Western Asia and the Middle East and relies on third‑party manufacturers and potential out‑licensing or collaborator distribution channels.
Summary from filing dated 2025-03-21
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 16 | 18 | 19 | 19 | 14 | |
| General and administrative | 9 | 9 | 10 | 12 | 8 | |
| Depreciation and amortization | 90,000 | 126,000 | 127,000 | 130,000 | 164,000 | |
| Total operating expenses | 25 | 27 | 30 | 31 | 23 | |
| Loss from operations | −25 | −27 | −30 | −31 | −23 | |
| Gain from change in fair value of warrant liabilities | 24 | 0 | −1 | 1 | 7 | |
| Loss on issuance of warrant liabilities | −31 | 0 | 0 | — | — | |
| Transaction costs allocated to warrant liabilities | −1 | 0 | −510,000 | 0 | — | |
| Loss on extinguishment of warrant liabilities | −614,000 | 0 | — | — | — | |
| Other (expense) income, net | −20,000 | 43,000 | 48,000 | 40,000 | 40,000 | |
| Interest income, net | 105,000 | 550,000 | 1 | 240,000 | — | |
| Net loss | −34 | −26 | −30 | −29 | −16 | |
| Warrant deemed dividend | −104,000 | 0 | — | — | — | |
| Net loss available to common stockholders | −34 | −26 | — | — | — | |
| Net loss per common share - basic and diluted (in dollars per share) | −28.42 | −189.14 | −15.07 | −15.22 | −0.59 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 1 | 137,720 | 2 | 2 | 27 | |
| Foreign currency translation | 51,000 | −32,000 | −21,000 | −29,000 | −24,000 | |
| Comprehensive loss | −34 | −26 | −30 | −29 | −16 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-05-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | — | 4 | 24 | 43 | |
| Prepaid expenses and other current assets | 808,000 | — | 916,000 | 3 | 2 | |
| Total current assets | 10 | — | 5 | 26 | 46 | |
| Furniture and equipment, net | 78,000 | — | 159,000 | 272,000 | 275,000 | |
| Intangible assets | 11 | — | 11 | 11 | 11 | |
| Other non-current assets | 900,000 | 900,000 | 0 | — | — | |
| Operating lease right-of-use asset | 314,000 | — | 424,000 | 524,000 | 403,000 | |
| Total Assets | 22 | — | 17 | 38 | 57 | |
| Accounts payable | 4 | — | 2 | 2 | 2 | |
| Accrued expenses and other current liabilities | 3 | — | 3 | 4 | 3 | |
| Total current liabilities | 7 | — | 5 | 7 | 5 | |
| Operating lease liability - long-term, net of current portion | 222,000 | — | 358,000 | 474,000 | 335,000 | |
| Warrant liability | 44,000 | — | 0 | 5 | 77,000 | |
| Total Liabilities | 7 | — | 6 | 12 | 5 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000,000 authorized shares, no shares issued or outstanding | 0 | — | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 500,000,000 and 100,000,000 authorized shares as of December 31, 2025 and December 31, 2024, respectively, 3,199,228 and 135,155 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | — | 0 | 33,000 | 29,000 | |
| Additional paid-in capital | 221 | — | 184 | 158 | 154 | |
| Accumulated other comprehensive income (loss) | 10,000 | — | −41,000 | — | — | |
| Accumulated deficit | −206 | — | −172 | −146 | −102 | |
| Total stockholders' equity | 15 | — | 11 | 31 | 52 | |
| Total liabilities and stockholders' equity | 22 | — | 17 | 38 | 57 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 2 | 2 | 2 | 2 | 2 | |
| Transaction costs allocated to warrant liabilities | 1 | 0 | 510,000 | 0 | — | |
| Operating lease, net | −26,000 | 103,000 | 119,000 | 92,000 | 96,000 | |
| Prepaid expenses and other assets | −792,000 | 2 | −272,000 | −857,000 | 431,000 | |
| Accounts payable | 1 | −468,000 | 403,000 | 731,000 | 235,000 | |
| Accrued expenses and other liabilities | 17,000 | −1 | 1 | 350,000 | 372,000 | |
| Net cash used in operating activities | −23 | −24 | −24 | −28 | −19 | |
| Purchase of fixed assets | 0 | −13,000 | −124,000 | −67,000 | −19,000 | |
| Net cash used in investing activities | 0 | −13,000 | −124,000 | −67,000 | −19,000 | |
| Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs | 26 | 5 | 4 | — | — | |
| Proceeds from exercise of warrants | 2 | 1,000 | 0 | 0 | 63,000 | |
| Payment of tax liability for vested restricted stock units | −8,000 | −26,000 | −25,000 | −23,000 | −23,000 | |
| Net cash provided by financing activities | 27 | 5 | 4 | −23,000 | 75 | |
| Net increase (decrease) in cash and cash equivalents | 5 | −19 | −20 | −28 | 56 | |
| Effect of exchange rate changes on cash and cash equivalents | 51,000 | −32,000 | −21,000 | −29,000 | −24,000 | |
| Reclassification of warrant liabilities to equity pursuant to warrant amendments | 17 | 0 | — | — | — | |
| Equity warrants issued in relation to liability-classified warrant inducements | 6 | 0 | — | — | — | |
| Offering costs included in accounts payable and accrued liabilities | 138,000 | 0 | 115,000 | 0 | — | |
| Deemed dividend in connection with warrant amendment | 104,000 | 0 | — | — | — | |
| Transaction costs related to the sale of common stock, pre-funded and common warrants | 0 | 156,000 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro